- OCM™ was significantly better than
comparators at halting proliferation of MRSA and PA –
-
OCM™ recorded the lowest bacterial counts of any treatment arm
–
- OCM™ showed significantly faster formation of new
tissue in MRSA-infected wounds than any other
treatment –
SARASOTA, Fla., May 20, 2024
/PRNewswire/ -- Omeza®, a regenerative skincare company
that develops marine-based therapies for the treatment of chronic
wounds, recently presented in vivo data showing that OCM™ wound
matrix alone significantly reduced methicillin-resistant
staphylococcus (MRSA) aureus and pseudomonas aeruginosa (PA)
bacterial counts and accelerated the formation of new tissue in
MRSA-infected wounds, outperforming a comparator treatment and a
control group.
Results of the in vivo data conducted in a porcine model—the
most similar to human skin in both morphological structure and
immunohistochemical properties1—were shown as a poster
during the Symposium on Advanced Wound Care (SAWC) conference
May 14 – 18.
"Stalled wounds affect more than 6.5 million Americans, with
devastating consequences for patients' physical, social, and mental
health," said Suzanne Bakewell,
Ph.D., Chief Scientific Officer at Omeza®. "Prolonged
wound healing times significantly increase the risk of severe
infection and resulting amputations, and thus they are a major
challenge for healthcare professionals who treat them."
"Limiting bacterial growth is a critical therapeutic aim in
treating nonhealing wounds, but complicating factors often prevent
success. OCM™ does not confer these complications, such as
antibiotic resistance, cytotoxicity, or viral transmission, and
we're excited by OCM™'s potential as a novel option for the
management of stalled wounds."
The current study was designed to evaluate the antimicrobial and
wound-healing effects of OCM™ against a comparator and a control in
a porcine wound model. OCM™ is a novel, propriety, drug/device
comprising cold-water fish peptides and other pharmaceutical-grade
ingredients that create an absorbable matrix which integrates into
the wound bed to support the synthesis of new tissue.
Study Design
In the study, wounds were inoculated with MRSA and PA, then
treated with either OCM™ alone and a silver dressing (positive
control) or debridement only (negative control). Wounds in all
groups were debrided, treated (except negative control), covered
with polyurethane dressings, and retreated on days 4 and 8. All
wounds were assessed on Days 4, 8, and 12 for bacterial counts,
among other measures.
Study Results
Results of the study showed the following:
- OCM™ alone was significantly better at halting proliferation in
both MRSA USA300- and PA27312-infected wounds compared with
baseline before and after debridement and compared with all other
treatment groups.
- Among all treatments at all time points, the lowest MRSA USA300
and PA27312 counts occurred on Day 12 in wounds treated with OCM™
alone.
- OCM™ showed significantly faster formation of new tissue in
MRSA USA300-infected wounds compared to the silver dressing and the
control group.
"These in vivo data constitute an important finding that may
have significant clinical implications for the management of many
wound etiologies, such as burns, diabetic foot ulcers, venous leg
ulcers, and pressure ulcers," said Dr. Windy Cole, DPM, adjunct professor and Director
of Wound Care Research at Kent State University College of
Podiatric Medicine.
"In recent years, researchers have amassed compelling evidence
of multiple pathways through which marine-derived ingredients exert
their effects on the immune system and wound healing at both the
cellular and molecular levels, including their ability to reduce
inflammation and increase metabolic activity of fibroblasts and
keratinocytes2-5, which are critical for protecting
against microbial invasion," said Dr. Cole.
"The in vivo study of OCM™ supports these foundational studies
and demonstrates that a specific therapy—OCM™—confers these
antimicrobial benefits in porcine wounds, and the potential is
likely in human wounds, as well," Dr. Cole said.
Omeza® is currently evaluating its platform in
three clinical studies among patients with diabetic foot ulcers,
venous leg ulcers, and chronic wounds of multiple wound etiologies
in a real-world setting. Among the endpoints are safety; change in
percent area reduction; ability to move wounds from chronicity to a
healing trajectory in a 4-week period; and time to complete wound
closure.
References:
1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547536/#:~:text=Porcine%20skin%20is%20often%20used,properties%20(15%E2%80%9318)
2https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.14506
3https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.14506
4https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117694/#B98-marinedrugs-16-00256
5https://www.hmpgloballearningnetwork.com/site/wmp/article/nutrition-411-omega-3-fatty-acids-and-wound-healing
About OMEZA
Omeza® is a commercial-stage regenerative skin and
wound-care company that develops marine-based products comprising
containing cold water fish peptides and other pharmaceutical-grade
components designed to reduce inflammation, increase tissue
proliferation, and support skin remodeling in adults with a range
of chronic, non-healing wounds. Founded in 2014, the company
currently markets OCM™ for the treatment of nonhealing wounds. OCM™
is also being evaluated in real-world settings and in multiple
clinical trials to compare the effects of OCM™ versus standard of
care on wound healing, pain reduction, quality of life, and other
secondary endpoints in patients with diabetic ulcers, chronic
venous leg ulcers, and multiple other wound types. The company is
headquartered in Sarasota,
Florida, and has manufacturing facilities located in
Florida.
Media Contacts:
Bernadette
Cupit
bcupit@omeza.com
908-334-4554
View original content to download
multimedia:https://www.prnewswire.com/news-releases/positive-data-from-in-vivo-study-shows-significant-antimicrobial-activity-of-ocm-against-methicillin-resistant-staphylococcus-aureus-mrsa-and-pseudomonas-aeruginosa-pa-in-porcine-wound-model-302150237.html
SOURCE Omeza LLC